Key Drivers
- High cash generation
- IP-driven margins
- Meaningful leverage
AIAI Summary
Gilead has shifted from a defensive, cash‑generator to a higher‑optionality, execution‑dependent growth story—buyers should now be betting on successful Arcellx integration and Trodelvy commercialization (and watch FCF/margin trends and debt levels closely), because these binary outcomes will determine whether the premium valuation is justified.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •High cash generation
- •IP-driven margins
- •Meaningful leverage
GILD delivers exceptional cash generation and returns (high margins, ROE/ROIC, and ~$9.46B FCF) backed by IP and R&D but carries meaningful leverage and a premium valuation.
Price Behavior
Key Price Behavior Insights:
- •Sustained selling
- •Near-term support
- •Resistance cap
GILD is in a clear short-term downtrend last month, sliding about 8.9% from ~$150.55 to ~$137.21 and trading near support around $137 with resistance at $150–$155.
~8.9% pullback last month from $150.55 to $137.21 indicating sustained selling pressure
Sentiment & News
Key News Insights:
- •Analyst attention
- •Mixed flows
- •Active presentations
Gilead drew heavy analyst and retail attention in March—backed by multiple conference presentations and M&A news—while showing short-term share volatility and mixed institutional buying and selling.
Continued analyst coverage and management visibility should keep Gilead in focus, but divergent institutional positioning may maintain near-term stock volatility
Similar Companies in Healthcare
Other companies in the same sector with AI ratings